Larson Bruce A, Lembela-Bwalya Deophine, Bonawitz Rachael, Hammond Emily E, Thea Donald M, Herlihy Julie
Center for Global Health and Development, Boston University, Boston, MA, United States of America.
Zambia Center for Applied Health Research and Development, Lusaka, Zambia.
PLoS One. 2014 Dec 5;9(12):e113868. doi: 10.1371/journal.pone.0113868. eCollection 2014.
In March 2012, The Elizabeth Glaser Pediatric AIDS Foundation trained maternal and child health workers in Southern Province of Zambia to use a new rapid syphilis test (RST) during routine antenatal care. A recent study by Bonawitz et al. (2014) evaluated the impact of this roll out in Kalomo District. This paper estimates the costs and cost-effectiveness from the provider's perspective under the actual conditions observed during the first year of the RST roll out.
Information on materials used and costs were extracted from program records. A decision-analytic model was used to evaluate the costs (2012 USD) and cost-effectiveness. Basic parameters needed for the model were based on the results from the evaluation study.
During the evaluation study, 62% of patients received a RST, and 2.8% of patients tested were positive (and 10.4% of these were treated). Even with very high RST sensitivity and specificity (98%), true prevalence of active syphilis would be substantially less (estimated at <0.7%). For 1,000 new ANC patients, costs of screening and treatment were estimated at $2,136, and the cost per avoided disability-adjusted-life year lost (DALY) was estimated at $628. Costs change little if all positives are treated (because prevalence is low and treatment costs are small), but the cost-per-DALY avoided falls to just $66. With full adherence to guidelines, costs increase to $3,174 per 1,000 patients and the cost-per-DALY avoided falls to $60.
Screening for syphilis is only useful for reducing adverse birth outcomes if patients testing positive are actually treated. Even with very low prevalence of syphilis (a needle in the haystack), cost effectiveness improves dramatically if those found positive are treated; additional treatment costs little but DALYs avoided are substantial. Without treatment, the needle is essentially found and thrown back into the haystack.
2012年3月,伊丽莎白·格拉泽儿童艾滋病基金会对赞比亚南部省的母婴健康工作者进行培训,使其在常规产前护理中使用一种新型梅毒快速检测(RST)。博纳维茨等人(2014年)近期开展的一项研究评估了在卡洛莫区推广该检测的影响。本文从提供者的角度,根据RST推广第一年实际观察到的情况,估算了成本和成本效益。
从项目记录中提取所用材料及成本的信息。使用决策分析模型评估成本(2012年美元)和成本效益。模型所需的基本参数基于评估研究的结果。
在评估研究期间,62%的患者接受了RST检测,检测呈阳性的患者占2.8%(其中10.4%接受了治疗)。即便RST具有很高的灵敏度和特异度(98%),活动性梅毒的实际患病率仍会低得多(估计<0.7%)。对于1000名新的产前护理患者,筛查和治疗成本估计为2136美元,每避免一个伤残调整生命年损失(DALY)的成本估计为628美元。如果所有阳性患者都接受治疗,成本变化不大(因为患病率低且治疗成本小),但每避免一个DALY的成本降至仅66美元。若完全遵循指南,每1000名患者的成本增至3174美元,每避免一个DALY的成本降至60美元。
只有对检测呈阳性的患者进行实际治疗,梅毒筛查才有助于减少不良分娩结局。即便梅毒患病率极低(大海捞针),若对检测呈阳性者进行治疗,成本效益会显著提高;额外的治疗成本很低,但避免的DALY却很多。若不进行治疗,基本上就是找到了针却又把它扔回了干草堆里。